ACAD - ACADIA Pharmaceuticals Inc.

Edited Transcript of ACAD earnings conference call or presentation 31-Jul-19 8:30pm GMT

Q2 2019 ACADIA Pharmaceuticals Inc Earnings Call

The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals ...

The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...

Acadia stock drops as schizophrenia drug doesn't pass clinical trial

Acadia Pharmaceuticals Inc. shares dropped in the extended session Monday after the biotech drug maker said its schizophrenia treatment did not pass a late-stage clinical trial. Acadia shares fell 15% after hours, following a 1.1% rise to close the regular session at $25.97. In a Phase 3 clinical trial, Acadia said that its treatment pimavanserin did not perform better than a placebo on a statistically significant basis when added to an existing antipsychotic treatment for schizophrenia. By Monday's close, Acadia shares had gained nearly 61% on the year, compared with a 19% rise in the S&P 500 index and a 24% gain in the Nasdaq Composite Index .

Acadia's schizophrenia treatment misses late-stage main goal; shares fall 16%

In the study, 396 patients with moderate-to-severe psychotic symptoms were given Acadia's treatment pimavanserin or placebo as an add-on to their current antipsychotic treatment, the company said. Adding pimavanserin to existing antipsychotic treatment showed a consistent trend in improvement of psychotic symptoms, however, the results did not show statistical significance in achieving the main goal, Acadia said.

Acadia's schizophrenia treatment fails to meet main goal of late-stage study

Acadia Falls Sharply in After-Hours Trading After Schizophrenia Drug Fails Study

Stock drops as Pimavanserin study finds no statistically significant improvement in adult schizophrenia patients.

See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACADView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for ACAD with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ACAD are favorable, with net inflows of $3.03 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

Edited Transcript of ACAD earnings conference call or presentation 1-May-19 8:30pm GMT

Q1 2019 ACADIA Pharmaceuticals Inc Earnings Call